Regan Stone, OD
Optometrist · Englewood, CONPI 1780322263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,642, 3.3 times the $491 reported in 2022. Among optometrist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $59.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$761
- Bausch & Lomb Americas Inc.$596
- Rxsight Inc$542
- Glaukos Corporation$541
- AbbVie$462
- Astellas Pharma US Inc$374
- plus $2K from 12 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$5,04399%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $761 |
| Bausch & Lomb Americas Inc. | 11 | $596 |
| Rxsight Inc | 6 | $542 |
| Glaukos Corporation | 5 | $541 |
| AbbVie | 10 | $462 |
| Astellas Pharma US Inc | 3 | $374 |
| Biotissue Holdings Inc. | 11 | $349 |
| Amgen(2 entities) | 3 | $282 |
| Nova Eye, Inc. | 1 | $205 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $162 |
| Harrow Eye, LLC | 4 | $162 |
| Sun Pharmaceutical Industries Inc. | 6 | $161 |
| Eyevance Pharmaceuticals LLC | 1 | $124 |
| Dompe US, Inc. | 1 | $122 |
| Novartis | 3 | $90 |
| Mallinckrodt Hospital Products Inc. | 4 | $71 |
| Thea Pharma Inc. | 2 | $36 |
| Tearlab Corp | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$376
- RXSIGHT INJECTOR CARTRIDGE$376
- RXSIGHT INJECTOR HANDPIECE$376
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$376
- Izervay$374
- INFUSE$366
- Hydrus Microstent$293
- TEPEZZA$261
- iDoseTR$255
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$228
- LIGHT ADJUSTABLE LENS (LAL)$149
- DAILIES TOTAL1$145
- IC-8 Apthera IOL$132
- Flarex$124
- DURYSTA$124
- Rocklatan$123
- Rhopressa$123
- Oxervate$122
- VUITY$112
How this compares
$5,068 in reported general payments places this provider in the 95th percentile of 1,025 optometrist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 13 | $15,993 |
| LumiganBimatoprost | 31 | $12,599 |
| Prednisolone Acetate | 75 | $3,407 |
| Latanoprost | 224 | $1,936 |
| Timolol Maleate | 53 | $1,414 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 64 | $932 |
| ValacyclovirValacyclovir Hcl | 12 | $610 |
| Doxycycline Hyclate | 17 | $583 |
| Brimonidine Tartrate | 34 | $527 |
| Dorzolamide Hcl | 23 | $392 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $236 |
| Diclofenac Sodium | 11 | $215 |
| Ofloxacin | 14 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $596 | $15,99313 claims |
| AbbVieLumigan | $462 | $12,59931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,025 optometrist providers in Colorado.
Other optometrist in Englewood
- Seamus MartinEnglewood$6K
- Cecelia KoettingAurora$458K
- Kaleb AbbottAurora$145K
- Joshua OlsonBoulder$80K
- Felicia PopowskiFt Carson$80K
- Lisa HamiltonLittleton$73K
- Kent GodfreyGreenwood Village$49K
- Jason OrtmanCastle Pines$45K
- Scott GundersonBroomfield$43K
- Scot MorrisConifer$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.